Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial
| Autor: | Molina, Jean-Michel, Rizzardini, Giuliano, Orrell, Catherine, Afani, Alejandro, Calmy, Alexandra, Oka, Shinichi, Hinestrosa, Federico, Kumar, Princy, Tebas, Pablo, Walmsley, Sharon, Grandhi, Anjana, Klopfer, Stephanie, Gendrano, Isaias, Eves, Karen, Correll, Todd A, Fox, Michelle C, Kim, Jason * |
|---|---|
| Zdroj: | In The Lancet HIV June 2024 11(6):e369-e379 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|